It also reduced intrapulmonary prothrombin fragments, which is intriguing since glucocorticoid treatment reduced plasma levels of TNF-α and IL-6 during human endotoxemia, but did not affect LPS-induced activation of coagulation systemically (14). The gene discussed is F2; the disease is serum lipopolysaccharide activity.